98%
921
2 minutes
20
A reliable identification of a high-risk state for upcoming seizures may allow for preemptive treatment and improve the quality of patients' lives. We evaluated the ability of prodromal symptoms to predict preictal states using a machine learning (ML) approach. Twenty-four patients with drug-resistant epilepsy were admitted for continuous video-electroencephalographic monitoring and filled out a daily four-point questionnaire on prodromal symptoms. Data were then classified into (1) a preictal group for questionnaires completed in a 24-h period prior to at least one seizure (n = 58) and (2) an interictal group for questionnaires completed in a 24-h period without seizures (n = 190). Our prediction model was based on a support vector machine classifier and compared to a Fisher's linear classifier. The combination of all the prodromal symptoms yielded a good prediction performance (area under the curve [AUC] = .72, 95% confidence interval [CI] = .61-.81). This performance was significantly enhanced by selecting a subset of the most relevant symptoms (AUC = .80, 95% CI = .69-.88). In comparison, the linear classifier systematically failed (AUCs < .6). Our findings indicate that the ML analysis of prodromal symptoms is a promising approach to identifying preictal states prior to seizures. This could pave the way for development of clinical strategies in seizure prevention and even a noninvasive alarm system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/epi.16804 | DOI Listing |
Neurology
October 2025
Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.
Background And Objectives: Years before diagnosis of Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA), mild prodromal manifestations can be detected. Longitudinal follow-up of people with prodromal synucleinopathy, particularly idiopathic/isolated REM sleep behavior disorder (iRBD), enables in-depth clinical phenotyping of early disease, which could facilitate stratification for clinical trials, provide the definition of appropriate end points, or predict phenoconversion more precisely. The aim of this study was to update and expand on previous studies assessing clinical evolution from iRBD to clinically diagnosed disease, up to 14 years before diagnosis.
View Article and Find Full Text PDFMov Disord Clin Pract
September 2025
Department of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.
Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).
Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.
Sleep Med Clin
September 2025
Department of Neurology, National Neuroscience Institute, Singapore 308433, Singapore; Signature Research Program in Neuroscience and Behavioral Disorders, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; Neuroscience Academic Clinical Program, Duke-NUS Medical School, Singapore
Sleep dysfunction in Parkinson's disease (PD) includes rapid eye movement sleep behavior disorder, restless leg syndrome, and excessive daytime sleepiness. These sleep-related manifestations may serve as prodromal signs of PD, particularly in carriers of pathogenic mutations in the genes implicated in familial and sporadic forms of PD. Study findings underscore the importance of differentiating mutation-specific sleep phenotypes in PD.
View Article and Find Full Text PDFSleep Med Clin
September 2025
Centre for Neurology, Academic Specialist Centre, Stockholm Health Services, Solnavägen 2, 11365 Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; Department of Neurology, Karolinska University Hospital, Bioclinicum J5:20, Stockholm 17164, Swede
Parkinson's disease is a neurodegenerative disorder with an increasing prevalence worldwide. The development of disease-modifying therapies remains a critical priority; however, early intervention is limited by the paucity of robust biomarkers for the prodromal stage. Sleep disturbances-particularly isolated rapid eye movement sleep behavior disorder (iRBD)-are emerging as key clinical markers of prodromal synucleinopathy, offering opportunities for early detection and risk stratification.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Introduction: In observational studies of preclinical AD, an arbitrary "baseline" can obscure where an individual is located along a theoretical continuum. Optimizing longitudinal trajectories can distill multiple, non-linearly distributed observations into a single metric and inform where an individual may be along the disease course.
Methods: We developed a cognitive time (c-time) metric based on longitudinal cognitive data (mean = 7.